Use of Statin Medications and Risk of Esophageal Adenocarcinoma in Persons with Barrett's Esophagus

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2012 Jan 14

PMID 22241250

Citations 27

Authors

Elizabeth D Kantor

Lynn Onstad

Patricia L Blount

Brian J Reid

Thomas L Vaughan

Affiliations

Soon will be listed here.

Abstract

Background: Persons with Barrett's esophagus experience increased incidence of esophageal adenocarcinoma and may benefit from use of preventives. Studies suggest that statin medications may have chemopreventive properties; we therefore assessed the association between statin use and progression to esophageal adenocarcinoma.

Methods: In a prospective cohort of 411 persons with Barrett's, Cox regression was used to calculate HRs for nonsteroidal anti-inflammatory drug (NSAID) and statin use accounting for variation in use during follow-up and adjusting for age, sex, and smoking.

Results: The HRs for statin use among all participants were 0.59 [95% confidence interval (CI), 0.26-1.33] and 0.68 (95% CI, 0.30-1.54) before and after further adjustment for NSAID use, respectively. Among persons with high-grade dysplasia, the HRs for statin use were 0.31 (95% CI, 0.11-0.86) and 0.41 (95% CI, 0.13-1.26) before and after adding NSAIDs to the model, respectively.

Conclusions: While the reduced risk of esophageal adenocarcinoma observed among statin users may be explained by chance, the point estimates are similar in magnitude to those previously reported for NSAID use in this cohort and are unlikely to be confounded by known risk factors.

Impact: Further study in larger cohorts and meta-analyses of the potential for statins to reduce risk of esophageal adenocarcinoma is warranted.

Citing Articles

A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer.

Khaghani A, Kasiri K, Heidari-Soureshjani S, Sherwin C, Mardani-Nafchi H Anticancer Agents Med Chem. 2024; 24(14):1029-1037.

PMID: 38812422 DOI: 10.2174/0118715206292712240522043350.

Role of Obesity, Physical Exercise, Adipose Tissue-Skeletal Muscle Crosstalk and Molecular Advances in Barrett's Esophagus and Esophageal Adenocarcinoma.

Bilski J, Pinkas M, Wojcik-Grzybek D, Magierowski M, Korbut E, Mazur-Bialy A Int J Mol Sci. 2022; 23(7).

PMID: 35409299 PMC: 8999972. DOI: 10.3390/ijms23073942.

Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center.

Dighe S, Yan L, Mukherjee S, McGillicuddy C, Hulme K, Hochwald S Cancers (Basel). 2021; 13(18).

PMID: 34572881 PMC: 8465866. DOI: 10.3390/cancers13184653.

Prevention Strategies for Esophageal Cancer-An Expert Review.

Marabotto E, Pellegatta G, Sheijani A, Ziola S, Zentilin P, De Marzo M Cancers (Basel). 2021; 13(9).

PMID: 34062788 PMC: 8125297. DOI: 10.3390/cancers13092183.

Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.

Elliott J, Reynolds J Front Oncol. 2021; 11:627270.

PMID: 33777773 PMC: 7994523. DOI: 10.3389/fonc.2021.627270.

References

Galipeau P, Li X, Blount P, Maley C, Sanchez C, Odze R . NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4(2):e67. PMC: 1808095. DOI: 10.1371/journal.pmed.0040067. View

Cook M, Chow W, Devesa S . Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009; 101(5):855-9. PMC: 2736840. DOI: 10.1038/sj.bjc.6605246. View

Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H . Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352(21):2184-92. DOI: 10.1056/NEJMoa043792. View

Vaughan T, Dong L, Blount P, Ayub K, Odze R, Sanchez C . Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005; 6(12):945-52. DOI: 10.1016/S1470-2045(05)70431-9. View

Ahern T, Pedersen L, Tarp M, Cronin-Fenton D, Garne J, Silliman R . Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011; 103(19):1461-8. PMC: 3186780. DOI: 10.1093/jnci/djr291. View

Bouterfa H, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn J . Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res. 2000; 20(4):2761-71. View

Zhong W, Wang C, Chang T, Lee W . Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003; 144(9):3852-9. DOI: 10.1210/en.2003-0098. View

Friedman G, Flick E, Udaltsova N, Chan J, Quesenberry Jr C, Habel L . Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2007; 17(1):27-36. DOI: 10.1002/pds.1507. View

Ogunwobi O, Beales I . Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol. 2008; 103(4):825-37. DOI: 10.1111/j.1572-0241.2007.01773.x. View

10.

Blais L, Desgagne A, LeLorier J . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000; 160(15):2363-8. DOI: 10.1001/archinte.160.15.2363. View

11.

Nguyen D, El-Serag H, Henderson L, Stein D, Bhattacharyya A, Sampliner R . Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009; 7(12):1299-304. PMC: 2789910. DOI: 10.1016/j.cgh.2009.06.001. View

12.

Singh H, Mahmud S, Turner D, Xue L, Demers A, Bernstein C . Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol. 2009; 104(12):3015-23. DOI: 10.1038/ajg.2009.574. View

13.

Kaye J, Jick H . Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90(3):635-7. PMC: 2409598. DOI: 10.1038/sj.bjc.6601566. View

14.

Khurana V, Sheth A, Caldito G, Barkin J . Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34(2):260-5. DOI: 10.1097/MPA.0b013e318030e963. View

15.

Jacobs E, Newton C, Thun M, Gapstur S . Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011; 71(5):1763-71. DOI: 10.1158/0008-5472.CAN-10-2953. View

16.

Khurana V, Bejjanki H, Caldito G, Owens M . Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007; 131(5):1282-8. DOI: 10.1378/chest.06-0931. View

17.

Hippisley-Cox J, Coupland C . Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010; 340:c2197. PMC: 2874131. DOI: 10.1136/bmj.c2197. View

18.

Kastelein F, Spaander M, Biermann K, Steyerberg E, Kuipers E, Bruno M . Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology. 2011; 141(6):2000-8. DOI: 10.1053/j.gastro.2011.08.036. View

19.

Sassano A, Platanias L . Statins in tumor suppression. Cancer Lett. 2008; 260(1-2):11-9. DOI: 10.1016/j.canlet.2007.11.036. View

20.

Nguyen D, Richardson P, El-Serag H . Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138(7):2260-6. PMC: 2883678. DOI: 10.1053/j.gastro.2010.02.045. View